Berinert Market Report 2026

Berinert Market Overview

• The Berinert market growth in the historic period has been driven by identification of c1 esterase inhibitor deficiency, approval of plasma derived hae therapies • Market expansion is supported by improved genetic screening for hae, expansion of rare disease centers • Growth Driver: Rising Prevalence Of Genetic Disorders Fuels Berinert Market Growth • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Berinert Market?

Berinert is a prescription medication containing C1 esterase inhibitor (human), a protein derived from human plasma. It is primarily used to treat hereditary angioedema (HAE), a rare genetic disorder characterized by episodes of severe swelling in various body parts, such as the face, hands, feet, abdomen, or airway. Berinert replaces the deficient or malfunctioning C1 esterase inhibitor protein in HAE patients. This protein helps regulate the complement and contact systems, which are involved in inflammation and blood vessel permeability. The main indication types of berinert are hereditary angioedema (HAE) and acquired angioedema (AAE). Hereditary angioedema is a genetic condition causing episodes of severe swelling in the limbs, face, gastrointestinal tract, or airways due to low levels of C1 esterase inhibitor (C1-INH). The distribution channels are hospital pharmacies, retail pharmacies, and online pharmacies, and end users are adults, geriatrics, and pediatrics.

What Is The Berinert Market Growth Forecast?

The growth in the forecast period can be attributed to improved genetic screening for hae, expansion of rare disease centers, growth in plasma fractionation capacity, better patient access programs, long term safety data availability. Major trends in the forecast period include rising diagnosis of hereditary angioedema, increased use of plasma derived therapies, hospital based acute hae management, focus on rapid on demand treatment, expansion of rare disease awareness programs.

What Are The Drivers Of The Berinert Market?

The rise in the prevalence of genetic disorders is expected to propel the berinert market going forward. A genetic disorder is a health condition caused by abnormalities in an individual's DNA, which can result from mutations in single or multiple genes, chromosomal changes, or a combination of genetic and environmental factors. The rising prevalence of genetic diseases is due to increased awareness and advancements in diagnostic technologies, as these enable earlier and more accurate detection of previously undiagnosed conditions. Berinert aids in managing genetic disorders by providing targeted C1 esterase inhibitor therapy, making it essential for patients with hereditary angioedema caused by C1 inhibitor deficiency. It enhances treatment effectiveness by rapidly controlling acute swelling attacks, improving patient safety, comfort, and overall quality of life. For instance, in July 2025, according to the National Blood Authority, an Australia-based blood management agency, there were 2,788 patients living with hereditary haemophilia A (HMA) in 2023–2024, up from 2,681 patients in 2022–2023. Therefore, the growing availability of genetic testing is driving the expansion of the Berinert industry. The rise in healthcare expenditure is expected to propel the growth of the berinert market going forward. Healthcare expenditure refers to the total amount of financial resources spent on healthcare services, including medical treatments, hospital care, medications, and public health initiatives, by governments, businesses, and individuals. The increasing demand for healthcare expenditure is due to the rising prevalence of chronic diseases, which require long-term and costly treatments. Healthcare expenditure enhances Berinert utilization by increasing access to specialized C1 esterase inhibitor therapies, making them more available for patients with hereditary angioedema. It supports better clinical outcomes by enabling investment in advanced treatment options, improving the management of acute swelling attacks and overall patient well-being. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure saw a 5.6% increase in nominal terms in 2023, an increase of 0.9% growth compared to 2022. Therefore, the rising healthcare expenditure is driving the growth of the Berinert industry. The growing geriatric population is expected to propel the growth of the berinert market going forward. The geriatric population refers to individuals who are generally 65 years of age or older, and it encompasses the elderly who may experience various health, social, and functional changes due to aging. The growing geriatric population is attributed to factors such as advancements in healthcare, improved living conditions, better nutrition, and increased life expectancy. Berinert helps the geriatric population by offering effective C1 esterase inhibitor therapy, making it valuable for older adults managing hereditary angioedema and related immune deficiencies. It improves treatment stability by reducing the severity of acute swelling episodes, enhancing patient comfort, safety, and overall quality of life. For instance, in July 2024, according to the UK Parliament's House of Commons Library, a UK-based government administration, in 2022, there were 12.7 million people aged 65 or older in the UK, representing 19% of the total population and this number is projected to rise to 22.1 million by 2072, accounting for 27% of the population. Therefore, the growing geriatric population is driving the growth of the berinert market.

Key Players In The Global Berinert Market

Major companies operating in the berinert market are CSL Behring

What Defines the Berinert Market?

The berinert market consists of sales of C1 esterase inhibitors, infusion pumps, autoinjectors, and prefilled syringes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Berinert Market Report 2026?

The berinert market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the berinert industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.